

Amendments to the Claims:

1. (currently amended) A conjugate ~~consisting essentially of~~ comprising an antibody Fab' fragment, covalently attached to a polyethylene glycol (PEG) molecule having an average molecular weight of at least 20 kD, wherein the apparent size of the conjugate is at least about 500 kD, and at least about 8 fold greater than the apparent size of the antibody fragment.

2-19. (canceled)

20. (previously amended) The conjugate of Claim 1 wherein the PEG has an average molecular weight of at least about 40 kD.

21-24. (canceled)

25. (previously amended) The conjugate of Claim 1 wherein in the PEG molecule is covalently attached to the hinge region of the antibody fragment.

26. (Previously amended) The conjugate of Claim 1 wherein the antibody fragment comprises an antigen binding site that binds to human interleukin-8 (IL-8).

27. (canceled)

28. (original) The conjugate of Claim 26 wherein the antibody fragment comprising the anti-human IL-8 antigen binding site is humanized.

29. (original) The conjugate of Claim 28 wherein the anti-human IL-8 antigen binding site comprises the complementarity determining region of a light chain polypeptide amino acid sequence selected from the group consisting of the 6G4V11N35A light chain polypeptide amino acid sequence of Fig. 36 (SEQ ID NO: 56) and the 6G4V11N35E light chain polypeptide amino acid sequence of Fig. 45 (SEQ ID NO: 62).

30. (canceled)

31. (original) A composition comprising the conjugate of Claim 1 and a carrier.

32. (original) The composition of Claim 31 that is sterile.

33. (original) The conjugate of Claim 1, wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment and nonproteinaceous polymer molecules that form the conjugate.

34. (original) The conjugate of Claim 1, wherein the covalent structure of the conjugate incorporates one or more nonproteinaceous labels, and wherein the covalent structure of the conjugate is free of any matter other than the antibody fragment, nonproteinaceous polymer and nonproteinaceous label molecules that form the conjugate.

35. (original) The conjugate of Claim 34 wherein at least one nonproteinaceous label is radiolabel.

36. (currently amended) A conjugate ~~consisting essentially of~~ comprising a Fab' fragment, attached to a single polyethylene glycol (PEG) molecule of at least 20 kD, wherein said conjugate has an apparent size of at least about 500 kD and at least about 8 fold greater than the apparent size of at the antibody fragment.